Chief Physician, Professor, and Doctoral Supervisor. Currently, he serves as the academic leader, Party branch secretary, and deputy administrative director of the Cardiac and Vascular Surgery Department at the First Affiliated Hospital of Harbin Medical University. He concurrently holds more than 20 positions, including Standing Committee Member of the Vascular Disease Committee of the China Western Returned Scholars Medical Association, Committee Member of the Minimally Invasive Cardiovascular Surgery Committee (CMICS) of the National Cardiovascular Disease Expert Committee, and Member of the Academic Committee of Harbin Medical University. He is an editorial board member or reviewer for several domestic and international journals such as "Thoracic Diseases," "Stem Cell International," "Chinese Journal of Clinical Thoracic and Cardiovascular Surgery," "Advances in Cardiovascular Diseases," and "Chinese Journal of Tissue Engineering Research." In 2011, he was sent to the Mars Centre of Toronto General Hospital in Canada for a one-year study and training, mentored by Professor Renke Li, a member of the Royal Society of Canada. He received comprehensive and standardized clinical and research training. In 2019, he was selected as an elite student of the "Wu Yingkai Medical Development Foundation."

He specializes in the interventional and minimally invasive closure of congenital heart diseases, endovascular repair and HyBrid treatment of aortic diseases. Additionally, he has profound expertise in off-pump coronary artery bypass surgery, heart valve reconstruction/replacement with concurrent radiofrequency ablation for atrial fibrillation, large vessel replacement, chronic pulmonary embolism endarterectomy, and pericardiectomy for constrictive pericarditis. Currently, he has published over 60 professional papers as the first or corresponding author, including 13 SCI papers with a total impact factor of 64.93. His representative works have been published in the authoritative journal in the international cardiovascular field, JACC, with a single impact factor of 14.086. This paper won the first prize of the "Vivien Thomas Young Investigator Award" at the 2012 American Heart Association (AHA) Annual Meeting, the first prize of the "Trainee Research Award" at the 2012 Canadian Cardiovascular Society (CCS) Annual Meeting, and the first prize of the "Best Paper Award" from the Society of Chinese Bioscientists in America (SCBA) in 2013. Another representative work was published in the top journal in the field of international biomaterials, Biomaterials (2020), with an impact factor of 12.479.

Currently, he has presided over one sub-project of the National Key Research and Development Program, two National Natural Science Foundation of China projects, and 19 other research projects, including the China Postdoctoral Fund, Heilongjiang Provincial Returned Scholars Fund, and Heilongjiang Provincial Returned Scholars Selective Startup Fund, with a total funding of approximately 6 million yuan. In 2014 and 2016, he was awarded the Outstanding Young Physician Paper Award by the Chinese Society of Thoracic and Cardiovascular Surgery, the "Lillehei Scholarship" and the "Earl Bakken Scholarship" by the same society. In 2014, he was named an outstanding youth of Harbin Medical University's "Yu Weihan" program. In 2017, he was selected for the "Outstanding Young Talent Cultivation Program" at the Second Affiliated Hospital of Harbin Medical University. In 2021, he was chosen as a "Xinglian Position Teacher" at Harbin Medical University.